We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$426M
AUM Growth
-$8.17M
Cap. Flow
-$21.9M
Cap. Flow %
-5.15%
Top 10 Hldgs %
33.1%
Holding
137
New
22
Increased
24
Reduced
54
Closed
27

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$7.8M
2
BIIB icon
Biogen
BIIB
+$7.48M
3
FOLD
Amicus Therapeutics
FOLD
+$6.39M
4
CYTK icon
Cytokinetics
CYTK
+$6.32M
5
TRVI icon
Trevi Therapeutics
TRVI
+$4.98M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$10.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.03M
3
NICE icon
Nice
NICE
+$5.13M
4
MRUS
Merus
MRUS
+$4.48M
5
SNY icon
Sanofi
SNY
+$4.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.73%
2 Technology 17.1%
3 Consumer Discretionary 1.67%
4 Utilities 1.53%
5 Communication Services 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
101
DELISTED
Kezar Life Sciences
KZR
$268K 0.06%
58,539
-49,934
-46% -$214K
CLYM
102
Climb Bio
CLYM
$692M
$260K 0.06%
209,837
-32,098
-13% -$39.9K
SLDB icon
103
Solid Biosciences
SLDB
$836M
$244K 0.06%
+50,190
New +$177K
PEPG icon
104
PepGen
PEPG
$123M
$174K 0.04%
+156,467
New +$221K
OKUR
105
OnKure Therapeutics
OKUR
$162M
$144K 0.03%
60,454
-20,000
-25% -$52.4K
ELEV
106
DELISTED
Elevation Oncology
ELEV
$121K 0.03%
328,562
-30,000
-8% -$10K
ELDN icon
107
CALL
Eledon Pharmaceuticals
ELDN
$263M
$84.6K 0.02%
+31,200
New +$93.6K
JSPR icon
108
Jasper Therapeutics
JSPR
$20.7M
$81.4K 0.02%
14,671
-107,346
-88% -$529K
APLT
109
DELISTED
Applied Therapeutics
APLT
$15.6K ﹤0.01%
50,000
– –
ALEC icon
110
Alector
ALEC
$180M
– –
-109,208
Closed -$134K
ARVN icon
111
Arvinas
ARVN
$536M
– –
-125,000
Closed -$878K
AVGO icon
112
Broadcom
AVGO
$1.85T
– –
-11,695
Closed -$1.96M
CHKP icon
113
Check Point Software Technologies
CHKP
$13.1B
– –
-8,334
Closed -$1.9M
FATE icon
114
Fate Therapeutics
FATE
$293M
– –
-397,177
Closed -$314K
FROG icon
115
JFrog
FROG
$9.5B
– –
-42,871
Closed -$1.37M
GOOG icon
116
Alphabet (Google) Class C
GOOG
$4.08T
– –
-13,500
Closed -$2.11M
IMTXW
117
DELISTED
Immatics N.V. Warrants
IMTXW
– –
-100,000
Closed -$1.58K
INZY
118
DELISTED
Inozyme Pharma
INZY
– –
-1,191,140
Closed -$1.08M
IONS icon
119
Ionis Pharmaceuticals
IONS
$8.81B
– –
-63,821
Closed -$1.93M
LVTX
120
DELISTED
LAVA Therapeutics
LVTX
– –
-48,420
Closed -$61.5K
MRUS
121
DELISTED
Merus
MRUS
– –
-106,532
Closed -$4.48M
NICE icon
122
Nice
NICE
$5.79B
– –
-33,303
Closed -$5.13M
NKE icon
123
Nike
NKE
$62.7B
– –
-30,050
Closed -$1.91M
NTR icon
124
Nutrien
NTR
$33.9B
– –
-30,894
Closed -$1.53M
OTLK icon
125
Outlook Therapeutics
OTLK
$194M
– –
-857,142
Closed -$1.05M
2 3 4
5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return

Sphera Funds Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sphera Funds Management held 137 positions worth $426M, down 1.9% from $434M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $21.9M in Q2 2025, closing 27 positions and reducing 54 holdings. Its most notable exit was Nice, an estimated $5.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Amicus Therapeutics worth $5.68M.

  • Sphera Funds Management's largest Q2 2025 buy was Amicus Therapeutics: 990,718 shares worth $5.68M.
  • Sphera Funds Management added most to Tower Semiconductor in Q2 2025, an estimated $7.8M increase.
  • Sphera Funds Management's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Nice in Q2 2025, selling an estimated $5.13M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $426M portfolio in Q2 2025.
  • Sphera Funds Management opened 22 new positions and closed 27 in Q2 2025.
  • Sphera Funds Management's portfolio value fell 1.9% quarter-over-quarter to $426M.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.